Related Experiment Video
Updated: Oct 2, 2026

A Protocol to Set Up Needle-Free Connector with Positive Displacement on Central Venous Catheter in Intensive Care Unit
Published on: July 13, 2019
Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock
Francesco Quarello1, Giacomo Forneris
1Nephrology and Dialysis Unit, San Giovanni Bosco Hospital, Turin, Italy. fquarello@tin.it
Insights
Totally implanted devices and taurolidine lock solutions show promise in reducing hemodialysis catheter infections. These innovations may improve vascular access reliability and patient outcomes by decreasing infection episodes.
Area of Science:
- Nephrology
- Infectious Diseases
- Biomaterials
Background:
- Central venous catheters used for hemodialysis have significant limitations, including thrombosis, stenosis, and catheter-related bloodstream infections (CRBI).
- CRBI necessitates catheter removal and prolonged antibiotic treatment, impacting patient health and healthcare costs.
Purpose of the Study:
- To evaluate the efficacy of a totally implanted vascular access device (Dialock) in reducing catheter-related infections compared to standard tunneled catheters.
- To assess the impact of a taurolidine-based lock solution (Neutrolin) on CRBI rates in patients undergoing hemodialysis.
Main Methods:
- A comparative study assessed infection rates between totally implanted devices and tunneled catheters.
- A separate study investigated the reduction in CRBI using a taurolidine-based lock solution with different catheter types.
Main Results:
- The totally implanted device demonstrated a significant reduction in overall catheter-related infections (0.97 vs. 4.75 episodes/1,000 catheter-days), primarily due to fewer local cutaneous infections.
- Bloodstream infection rates were similar between the totally implanted device and tunneled catheters.
- The taurolidine-based lock solution significantly decreased CRBI rates to 0.29 and 0.20 episodes/1,000 catheter-days for subcutaneous ports and tunneled catheters, respectively.
Conclusions:
- Totally implanted vascular access devices may offer improved protection against local catheter-related infections.
- Taurolidine-based lock solutions show significant potential in reducing CRBI during hemodialysis.
- Further clinical trials are needed to confirm these promising findings for vascular access management.
Abstract:
Among currently available vascular access options for hemodialysis, central venous catheters show the poorest reliability, with frequent complications of thrombosis and stenosis impairing patency. The most serious problem, however, is catheter-related bloodstream infection (CRBI), which is typically a cause for removal of the catheter and protracted systemic antibiotic therapy. In our experience, a totally implanted device (Dialock, Biolink Corp.) seems to confer a better global protection against catheter-related infections than standard tunneled catheters, accounting for 0.97 vs. 4.75 infection episodes/1,000 catheter-days, respectively (p < 0.001). Bloodstream infection rates, however, are not statistically different in the two groups (0.85 vs. 0.81 per 1,000 catheter-days; p = n.s.), indicating that the improvement is mainly related to local cutaneous infections. On the other hand, in the Sodemann experience, a new taurolidine-based lock solution (Neutrolin, Biolink Corp.) greatly reduced CRBI rates with both subcutaneous ports and tunneled catheters to 0.29 and 0.20 episodes/1,000 catheter-days, respectively. These promising results await further confirmation from ongoing clinical trials.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
Endocarditis IV: Nursing Management
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Cardiac Catheterization I: Pre-Procedure Overview
